Semaglutide TFA (Ozempic, GLP-1 receptor agonist)-Therapeutic peptides drug benchmark for in-vivo/in-vitro study

Semaglutide TFA, the trifluoroacetic acid salt form of Semaglutide. Semaglutide acts like human glucagon-like peptide-1 (GLP-1) such that it increases insulin secretion, thereby increasing sugar metabolism. Semaglutide, sold under the brand name Ozempic among others, is an anti-diabetic medicationused for the treatment of type 2 diabetes and chronic weight management.

Order information

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-peptide-004-5mg	5mg	780
GMP-Bios-peptide-004-25mg	25mg	1950
GMP-Bios-peptide-004-50mg	50mg	2925
GMP-Bios-peptide-004-100mg	100mg	3900
GMP-Bios-peptide-004-500mg	500mg	7800
GMP-Bios-peptide-004-xmg	≥500mg	Inquiry
			Shipping Cost:	760.00
			Total:

For more than 500mg, click here for inquiry. >>

Description

Product Name	Semaglutide TFA
Brand name	Ozempic
CAS No.	910463-68-2
Formula	C189H292F3N45O61
Biological Activity	Semaglutide acts like human glucagon-like peptide-1 (GLP-1) such that it increases insulin secretion.
Purity	Purity: ≥98% (HPLC)
Application	Therapeutic peptides drug benchmark or raw material for peptide drugs or peptide conjugation drugs discovery and development.
Predicted Molecular Mass	4210.63
Formulation	Powder
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

GENEMEDI: 6th Floor, Building No.2, Kangxin Road 3377, Shanghai, China; Email: [email protected] [email protected]; Telephone: +86-21-50478399 Fax: 86-21-50478399; Privacy Policy